Changes
/* Dolcera Dashboard */
*'''''What is it?''''' A ureteral stent is a specially designed hollow tube, made of a flexible plastic material that is placed in the ureter.
*'''''Need for a ureteral stent:''''' In patients who have, or might have, an obstruction (blockage) of the kidney, an internal drainage tube called a ‘stent’ is commonly placed in the ureter, the tube between the kidney and the bladder. This is placed there in order to prevent or temporarily relieve the obstruction.
==Background==
[[Image:Ureteral_Stent.png|thumb|200px|<center>[http://www.pnnmedical.com/urology/professionals/products/memokath%E2%84%A2-051-ureter.aspx '''Ureteric Stent''']</center>]]
Ureteral stents are used in urological surgery to maintain patency of the ureter to allow urine drainage from the renal pelvis to the bladder. These devices can be placed by a number of different endourological techniques. They are typically inserted through a cystoscope and may also be inserted intraoperatively. Indwelling ureteral stents help to reduce complications and morbidity subsequent to urological and surgical procedures. Frequently, ureteral stents are used
to facilitate drainage in conjunction with Extracorporeal Shock Wave Lithotripsy (ESWL) and after endoscopic procedures. They are also used to internally support anastomoses and prevent urine leakage after surgery. Ureteral stenting may almost eliminate the urological complications of renal transplantation.
An antimicrobial ureteral stent, which inhibits encrustation and bacterial colonization while maintaining patient comfort.
* Ureteral stent: resists migration, resists fragmentation, is kink resistant and radiopaque.
* Bacterial colonization: antimicrobial activity for up to two weeks.
* Patient Comfort: stent has a low coefficient of fiiction friction (value) for ease of insertion and will soften on implant at body temperature to maintain patient comfort.
'''[[more on market overview...]]''' === Ureteric stenting difficulties ==Interactive Mind Map=* To access the Dashboard you have to signup. You can do so by clicking [[Imagehttps:Ureteral stent//www.jpg|thumb|right|350px|Double-J and Pigtail ureteral stents]dolcera.com/auth/index.php/login '''here''']*''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy''*''Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard'' *''Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap''{|border="2" cellspacing="20" cellpadding="4" width="50100%"|align = "center" bgcolor = "#00CCFF"|<font color="#993366"mm>'''Common'''</font>[[Ureteral_Stent_Patent_Categorization.mm|align = "center" bgcolor = "#00CCFF"flash|<font color="#993366">'''Rare'''Patent Categorization|600pt]]</fontmm>
|}
==New trials == Encrustation ====The urinary system presents a challenge because of its chemically unstable environment. Long-term biocompatibility and biodurability of devices have been problems due to the supersaturation of uromucoids and crystalloids at the interface between urine and the device. Encrustation of ureteral stents is a well-known problem, which can be treated easily if recognized early. However, severe encrustation leads to renal failure and is difficult to manage (Mohan-Pillai et al., 1999). All biomaterials currently used become encrusted to some extent when exposed to urine.
{| border="2" cellspacing="0" cellpadding="4" width=Infection"100%"| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''S.No. '''</font></center>| style="background-color:#4f81bd;padding:0.079cm;"|<center><font color="#FFFFFF">'''Company '''</font></center>The predictive value | style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Device '''</font></center>| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Approval '''</font></center>| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Date of urine cultures in the assessment of stent colonization was examined in 65 patients with indwelling ureteral stentsApproval '''</font></center>| style="background-color:#4f81bd;padding:0. It was found that a sterile urine culture did not rule out the stent itself being colonized (Lifshitz, et al079cm;"| <center><font color="#FFFFFF">'''Material '''</font></center>| style="background-color:#4f81bd;padding:0., 1999079cm;"| <center><font color="#FFFFFF">'''Technology '''</font></center>| style="background-color:#4f81bd;padding:0.079cm;"| <center><font color="#FFFFFF">'''Indwelling Time (days)'''</font></center>|-| style="background-color:#dce6f1;padding:0. Patients with sterile urine culture079cm;"| <center>'''1'''</center>may benefit from prophylactic antibiotics| style="background-color:#dce6f1; however, the authors contended that the antibiotics must work against grampadding:0.079cm;"| <center>[http://www.bardurological.com/products/categoryTwo.aspx?bUnitID=3&catOneID=71 Bard Urological]</center>| style="background-negative uropathogens and gramcolor:#dce6f1;padding:0.079cm;"| <center>[[Image:InLay_Optima.png|thumb|center|100px|<center>InLay Optima</center>|[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3∏ID=225 <center>InLay Optima</center>]]]| style="background-positive bacteria including enterococcicolor:#dce6f1;padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=16869 FDA 510(k)]</center>It is obvious that there is controversy in the literature whether prophylactic systemic antibiotics are useful | style="background-color:#dce6f1;padding:0.079cm;"| <center>Dec 2004</center>| style="background-color:#dce6f1;padding:0.079cm;"| Silicone| style="background-color:#dce6f1;padding:0.079cm;"| Double pigtail with ureteral stent implantmonofilament suture loop| style="background-color:#dce6f1;padding:0. However079cm;"| <center>365</center>|-| style="padding:0.079cm;"| <center>'''2'''</center>| style="padding:0.079cm;"| <center>[http://www.bostonscientific.com/Device.bsci/, antibiotics do not seem to prevent stent colonization,/method/DevHome/navRelId/1000. Denstedt et al1003/seo. serve Boston Scientific]</center>| style="padding:0.079cm;"| [[Image:Polaris_Loop.png|thumb|center|100px|[http://www.bostonscientific.com/urology-stone/product.html?method=product_detail∏uct_id=10122561#initialLoad1(1998) have found that ciprofloxacin, <center>Polaris Loop</center>]]]| style="padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=10929 FDA 510(k)]</center>| style="padding:0.079cm;"| <center>Mar 2003</center>| style="padding:0.079cm;"| Dual Durometer Percuflex with a HydroPlus Coating| style="padding:0.079cm;"| Bladder loop design| style="padding:0.079cm;"| <center>365</center>|-| style="background-color:#dce6f1;padding:0.079cm;"| <center>'''3 day burst every '''</center>| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.cookmedical.com/uro/familyListingAction.do?family=Ureteral+Stents Cook Medical]</center>| style="background-color:#dce6f1;padding:0.079cm;"| [[Image:Resonance.png|thumb|center|100px|[http://www.cookmedical.com/uro/dataSheet.do?id=4418 <center>Resonance</center>]]]| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=23620 FDA 510(k)]</center>| style="background-color:#dce6f1;padding:0.079cm;"| <center>May 2007</center>| style="background-color:#dce6f1;padding:0.079cm;"| Metal| style="background-color:#dce6f1;padding:0.079cm;"| Temporary stenting| style="background-color:#dce6f1;padding:0.079cm;"| <center>365</center>|-| style="padding:0.079cm;" rowspan="2"| <center>'''4'''</center>weeks, actually is adsorbed onto the stent which makes longer term treatment possible with reduced risk of bacterial resistance| style="padding:0. There has been research targeted at coating or impregnating urinary catheters with antimicrobials and products are on the market, however, there are no antimicrobial ureteral stents approved by the 079cm;" rowspan="2"| <center>[http://www.fossamedical.com/news.htm Fossa Medical]</center>| style="padding:0.079cm;" rowspan="2"| [[Image:Stone_Sweeper.png|thumb|center|100px|[http://dolcera.com/upload/files/stonesweeper_fossa_trial.pdf <center>Stone Sweeper</center>]]]| style="padding:0.079cm;"| <center>[http://www.fossamedical.com/news.htm FDA510(k)]</center>| style="padding:0.079cm;"| <center>Aug 2002</center>| style="padding:0.079cm;" rowspan="2"| Polyurethane| style="padding:0.079cm;" rowspan="2"| Spiral radially expanding stent| style="padding:0.079cm;" rowspan="2"| <center>13</center>|-| style="padding:0.079cm;"| <center>[http://www.fossamedical.com/news.htm CE Mark]</center>| style="padding:0.079cm;"| <center>Sep 2005</center>
|-| style="background-color:#dce6f1;padding:0.079cm;"| <center>'''5'''</center>| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.pnnmedical.com/urology/professionals/products/memokath™-051-ureter.aspx Pnn Medical A/S]</center>| style= The market need "background-color:#dce6f1;padding:0.079cm;"| [[Image:Memokath_051.png|thumb|center|100px|[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CC4QFjAD&url=http://www.hammer.pl/pliki/147_2.pdf&rct=j&q=memokath%20051&ei=MfhATezNIoaqvQP-_ZGtAw&usg=AFQjCNFR-ZFsu33rk6B9Flq1tCsYBZyXMw&cad=rja <center>Memokath 051</center>]]]It is clear that there is a need for a new material that will be able to resist encrustation and infection in the urinary tract| style="background-color:#dce6f1;padding:0.079cm;"| <center>[http://www.pnnmedical.com/about-pnn-medical/company-history. According to Merrill Lynch, ureteral stents represent an $80 MMaspx CE Mark]</center>US market| style="background-color:#dce6f1;padding:0. Boston Scientific is in the lead with ~50% of the market followed by Maxxim (Circon), Cook and Bard is a smaller player079cm;"| <center>1995</center>| style="background-color:#dce6f1;padding:0. There are a number of other small contenders079cm;"| Nickel-titanium shape memory alloy| style="background-color:#dce6f1;padding:0. 079cm;"| Double fluted ended spiral stent| style="background-color:#dce6f1;padding:0.079cm;"| <center>240</center>|}
The use of ureteral stents for patients having ESWL for renal calculi is however controversial and seems to be related to the size of the stones and invasiveness of the procedureFDA classifies a ureteric stent as follows: * TITLE 21 - FOOD AND DRUGS* CHAPTER I - FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES* SUBCHAPTER H - MEDICAL DEVICES* PART 876 - GASTROENTEROLOGY-UROLOGY DEVICES* Subpart E - Surgical Devices* Sec. According to survey results reported by Hollowell, et al876. (2000), there is a significant difference in opinion concerning the use of stents with ESWL4620 - Ureteral stent. * Classification - class II device [http://www.accessdata.fda.gov/SCRIPTS/cdrh/cfdocs/cfCFR/CFR.cfm?fr=876.4620&Term=ureter%20stent Code of Federal Regulations]
|-|align ="center" rowspan ="2"|'''2'''|align = Intellectual property ="center" rowspan ="2"|<font color="#0000FF">[http://www.pnnmedical.com/urology/professionals/products/memokath™-051-ureter.aspx Pnn Medical A/S]</font>|align ="center" rowspan ="2"|[http://www.google.com/url?sa=t&source= Search strategy web&cd=4&ved=0CC4QFjAD&url=http://www.hammer.pl/pliki/147_2.pdf&rct=j&q=memokath%20051&ei=MfhATezNIoaqvQP-_ZGtAw&usg=AFQjCNFR-ZFsu33rk6B9Flq1tCsYBZyXMw&cad=rja Memokath 051]* Databases searched|align = "center"|<font color="#0000FF">[http: US//www.pnnmedical.com/about-G, USpnn-A, EPmedical/company-A, EP-B, WO, JP, DE, GB, FRhistory.aspx CE Mark]</font>* Search scope: Title, Abstract or Claims|align = "center"|1995* Years: 1981|rowspan = "2"|Nickel-July 2008titanium shape memory alloy* Search query: (ureter* OR urether* OR ureth* OR uretr*) AND (|rowspan = "2"|Double fluted ended spiral stent*) AND (*microb* OR *bacter*)* Results|align = "center" rowspan = "2"|240|rowspan = "2"|[[Image: '''177 patents (82 unique patent families)'''Memokath_051.png|thumb|center|100px|<center>Memokath 051</center>]]
|-
|-
|-
|-
|}align ="center" bgcolor ="#dce6f1" rowspan = Clinical Trials ="2"|[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K033368 Open lumen stent]|align ="center" bgcolor ="#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=New trials PMN&ID=K033368 FDA 510(k)]</u></font>|align ="center" bgcolor =={"#dce6f1"| {{table}}Nov, 2003| alignbgcolor ="center#dce6f1" rowspan = "2"|'''Title'''Polyurethane| alignbgcolor ="center#dce6f1" rowspan = "2"|'''Conditions'''Pigtail-tipped stent with <nowiki>’</nowiki>Pusher<nowiki>’</nowiki>| align="center" bgcolor = "#dce6f1" rowspan = "2"|'''Intervention'''| align="center" bgcolor = "#dce6f1" rowspan = "2"|'''Sponsors and Collaborators'''[[Image:Open_Lumen.png|thumb|center|100px|<center>Open_lumen</center>]]
|-
| align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://clinicaltrialswww.govfossamedical.com/ct2news.htm CE Mark]</showu></NCT00250406?termfont>|align =ureteral+stent&rank"center" bgcolor =1 Assessment of Drug-Eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation]||Renal Calculi, Ureteral Obstruction||Device: Ureteral Stent|"#dce6f1"|Lawson Health Research InstituteSep, Boston Scientific Corporation2005
|-
|align = "center" bgcolor = "#dce6f1"| [http://clinicaltrialswww.accessdata.fda.gov/ct2scripts/showcdrh/NCT00270504cfdocs/cfPMN/PMNSimple.cfm?termdb=urethral+stentPMN&rankID=1 Memokath® 044TW K021140 Expanding Ureteral Stent for Treatment of Urethral Stricture]|align = "center" bgcolor = "#dce6f1"|Urethral Stricture<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/PMNSimple.cfm?db=PMN&ID=K021140 FDA 510(k)]</u></font>|align = "center" bgcolor = "#dce6f1"|Device: Memokath stentingJun, 2002|bgcolor = "#dce6f1"|Engineers & Doctors Wallsten Medical GroupPolyurethane|bgcolor = "#dce6f1"|Double pigtail stent with <nowiki>’</nowiki>Pusher<nowiki>’</nowiki>|align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"| N/A
|-
| align = "center" rowspan = "7"|'''4'''|align = "center" rowspan = "7"|<font color="#0000FF"><u>[http://clinicaltrialswww.govbostonscientific.com/ct2Device.bsci/show,,/NCT00581178?termmethod/DevHome/navRelId/1000.1003/seo.serve Boston Scientific]</u></font>|align =urologic+stent&rank"center"|<font color=3 Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation]"#0000FF"><u>Contour</u></font>|align = "center"|Kidney Stones|align = "center"|N\A|Percuflex - proprietary polyolefin copolymer; Hydroplus coating|University of California, IrvineFixed and variable length; Tapered tip|align = "center"|365|align = "center" |[[Image:Contour.png|thumb|center|100px|<center>Contour</center>]]
|-
| [http:align = "center"|<font color="#0000FF"><u>Percuflex</u></clinicaltrials.gov/ct2/show/NCT00288457?termfont>|align =urologic+stent&rank"center"| |align =14 Ureteral Stent Length and Patient Symptoms]"center"||Kidney Stonesalign = "center"|Percuflex|DevicePigtail|align = "center"|365|align = "center" |[[Image: Ureteral StentPercuflex.png|thumb|Emory Universitycenter|100px|<center>Percuflex</center>]]
|-
| align = "center"|<font color="#0000FF"><u>Polaris Ultra</u></font>|align = "center"|<font color="#0000FF"><u>[http://clinicaltrialswww.accessdata.fda.gov/ct2scripts/showcdrh/NCT00166361cfdocs/cfPMN/PMNSimple.cfm?termdb=urologic+stentPMN&rankid=1 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral StentK010002 FDA 510(k)]</u></font>|align = "center"|Ureteral ObstructionJan, 2001|Dual Durometer Percuflex with HydroPlus Coating; soft Nautilus Bladder Coil.|DeviceDouble pigtail|align = "center"|365|align = "center" |[[Image: Memokath 051 Ureteral StentPolaris_Ultra.png|thumb|Mayo Clinic Engineers & Doctors Wallsten Medical Groupcenter|100px|<center>Polaris Ultra</center>]]
|-
| align = "center"|<font color="#0000FF"><u>Polaris Loop</u></font>|align = "center"|<font color="#0000FF"><u>[http://clinicaltrialswww.accessdata.fda.gov/ct2scripts/showcdrh/NCT00739284cfdocs/cfPMN/pmn.cfm?termID=urologic+stent&rank=15 A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney 10929 FDA 510(JJVsPCN08k)]</u></font>|align = "center"|Kidney DiseaseMar, 2003|Dual Durometer Percuflex with HydroPlus Coating|DeviceBladder loop design|align = "center"|365|align = "center" |[[Image: nephrostomy tube and ureteral stentPolaris_Loop.png|thumb|Rabin Medical Centercenter|100px|<center>Polaris Loop</center>]]
|-
|}align ="center"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source= Concluded trials web&cd=4&ved=0CCkQFjAD&url=http://www.bostonscientific.com/templatedata/imports/Microsite/Stone-EU/collateral/stone-eu-percuflex-brochure-eng.pdf&rct={| {{table}}j&q=percuflex%20brochure&ei=bIE-Tb79HMnqrAf5-_HRCA&usg=AFQjCNEJ-JOc Retromax Plus]</u></font>| align="center" |'''Title'''| align="center" |'''Abstract'''| align="center" Percuflex material and Hydroplus coating|'''Enrollment'''Endopyelotomy stent| align="center" |'''Disorder'''Post-procedure healing| align="center" |'''Conclusion'''[[Image:Retromax_plus.png|thumb|center|100px|<center>Retromax Plus</center>]]
|-
| Longalign = "center"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source=web&cd=4&ved=0CCkQFjAD&url=http://www.bostonscientific.com/templatedata/imports/Microsite/Stone-term outcome of permanent urethral stents in the treatment of detrusorEU/collateral/stone-sphincter dyssynergia ||To evaluate the longeu-term efficacy of a permanently implanted urethral stent in the treatment of spinally injured patients with detrusorpercuflex-sphincter dyssynergiabrochure-eng.pdf&rct=j&q=percuflex%20brochure&ei=bIE-Tb79HMnqrAf5-_HRCA&usg=AFQjCNEJ-JOc Stretch VL Flexima]</u></font>|align = "center"|13|align = "center"|Detrusor-sphincter dyssynergia|Hydroplus Coating|Stenting is an effective alternative to sphincterotomy in the long-term, although secondary bladder neck obstruction is a frequent problemVariable length coil on distal and proximal ends|align = "center"|90|align = "center" |[[Image:Stretch_VL_Flexima.png|thumb|center|100px|<center>Stretch VL Flexima</center>]]
|-
| Nephrostomy Tube or 'JJ' Ureteric Stent in Ureteric Obstructionalign = "center"|[http: Assessment of Patient Perspectives Using Quality//dolcera.com/upload/files/drug_eluting_ureteral_stent.pdf Drug-of-Life Survey and Utility AnalysisEluting Stent]|align = "center"|Upper urinary tract obstruction is often relieved by either a percutaneous nephrostomy tube (PCN) or a ureteric stent. Both can cause considerable morbidity and reduce patient's health|align = "center"| |Percuflex -related quality of life (QoL). We have compared the QoL in these 2 groups.proprietary polyolefin copolymer|Ketorolac trimethamine loaded stent|34align = "center"||Upper urinary tract obstructionalign = "center"||Patients with 'JJ' stents have significantly more irritative urinary symptoms and a high chance of local discomfort than patients with nephrostomy tubes (PCN). However, based on the EuroQol analysis, there is no significant difference in the gross impact on the health-related QoL or the utility between these groups indicating no patient preference for either modality of treatment.N/A
|-
| Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial.align = "center" bgcolor = "#dce6f1" rowspan = "6"|'''5'''|A randomized, prospective trial to compare the incidence of early urological complications and health care expenditures in renal transplant recipients with or without ureteral stenting.||201align = "center" bgcolor = "#dce6f1" rowspan = "6"||Renal transplant recipient||Using a ureteral stent at renal transplantation significantly decreases the early urinary complications of urine leakage and obstruction<font color="#0000FF">[http://www. However, there is a significant increase in urinary tract infections, primarily beyond 30 days after transplantationcookmedical. Stent removal within 4 weeks of insertion appears advisablecom/uro/familyListingAction.do?family=Ureteral+Stents Cook Medical]</font>|} align ="center" bgcolor ="#dce6f1"|<font color= Products "#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=4418 Resonance]</u></font>|align ="center" bgcolor ={"#dce6f1"| {{table}}<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=23620 FDA 510(k)]</u></font>| align="center" bgcolor = "#dce6f1"|'''Boston Scientific ScimedMay, Inc.'''2007|bgcolor = "#dce6f1"|Metal|bgcolor = "#dce6f1"| | align="center" bgcolor = "#dce6f1"|'''Cook Urological Incorporated'''365| align="center" bgcolor = "#dce6f1"|'''OptiMed Global Care'''[[Image:Resonance.png|thumb|center|100px|<center>Resonance</center>]]
|-
| Polaris™ Ultra Ureteral Stent align = "center" bgcolor = "#dce6f1"| Firlit<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=2055 Sof-Kluge Urethral Stentflex]</u></font>| Optialign = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|AQ® Hydrophilic Coating|bgcolor = "#dce6f1"|Radiopaque tip and tether for repositioning |align = "center" bgcolor = "#dce6f1"|180|align = "center" bgcolor = "#dce6f1"|[[Image:Sof_flex.png|thumb|center|100px|<center>Sof-J Ureteral Stent System flex</center>]]
|-
| Polaris™ Loop Ureteral Stentalign = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=3627 Endo-Sof]</u></font>| Koyle Diaper Stent align = "center" bgcolor = "#dce6f1"| | Ureteral Stent Sets, ureterorenoscope align = "center" bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|AQ® Hydrophilic Coating|bgcolor = "#dce6f1"|Double pigtail|align = "center" bgcolor = "#dce6f1"|365|align = "center" bgcolor = "#dce6f1"|[[Image:Endo_Sof.png|thumb|center|100px|<center>Endo-Sof</center>]]
|-
| Stretch™ VL Variable Length Flexima® Stents align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=3643 C-Flex]</u></font>| Silicone Universal Drainage Stentalign = "center" bgcolor = "#dce6f1"| | Extra Strong Stent Sets (align = "center" bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|Double Pigtail|align = "center" bgcolor = "#dce6f1"|180|align = "center" bgcolor = "#dce6f1"|[[Image:C_Flex.png|thumb|center|100px|<center>C-Tumor)Flex</center>]]
|-
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/dataSheet.do?id=4692 Smith Universal]</u></font>| Tarkington Urethral Stent Setalign = "center" bgcolor = "#dce6f1"| | Steerable align = "center" bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|Nephrostomy tube <nowiki>+</nowiki> Ureteral Stent Setsstent|align = "center" bgcolor = "#dce6f1"|60|align = "center" bgcolor = "#dce6f1"|[[Image:Smith_Universal.png|thumb|center|100px|<center>Smith Universal</center>]]
|-
|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/90717.php Endo-Sof Radiance]</u></font>| Zaontz Urethral Stentalign = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.medicalnewstoday.com/articles/90717.php Launch]</u></font>| Multilength align = "center" bgcolor = "#dce6f1"|Dec, 2007|bgcolor = "#dce6f1"|Heparin-bonded stent|bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|
|-
|align = "center"|'''6'''| align = "center"|<font color="#0000FF">[http://qurological.com/product/ Q Urological]</font>|align = "center"|<font color="#0000FF"><u>[http://qurological.com/product/ pAguaMedicina™ Pediatric Urethral C-Ureteral Stent]</u></font>|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=29056 FDA 510(k)]</u></font>|align = "center"|Jan, 2010|Hydrogel|Differentially larger end (no pigtail)|align = "center"|30|align = "center" |[[Image:pAguaMedicina.png|thumb|center|100px|<center>pAguaMedicina</center>]]
|-
|} == Phase 2: Deeper Dive align ="center" bgcolor ="#dce6f1"|'''7'''|align ="center" bgcolor ="#dce6f1"|<font color= Scenario ===Client wishes to acquire a ureteral stent company"#0000FF">[http://www. bioteq.com.tw/en/products.php?kind=2&series== Deal analysis for a target company ===[[Image:DealImplications4 Bioteque Corp.jpg|thumb|center|700px|Deal implications]]</font> === Design History File Review: Review components ==={| classalign ="wikitablecenter" stylebgcolor ="font-size:90%#dce6f1" border|Ureteral Stent Set|align ="1center" cellpaddingbgcolor ="5#dce6f1" cellspacing="0" |- style<font color="background:lightgrey#0000FF"><u>[http://www.bioteq.com.tw/en/news_detail.php?id=1&query_string= FDA 510(k) ]</u></font>!|align = "center" bgcolor = "#00CCFFdce6f1" width|Apr, 2010|bgcolor ="15%#dce6f1"|Review !|bgcolor = "#00CCFFdce6f1" width| |align ="30%center"|Verification!bgcolor = "#00CCFFdce6f1" width|30|align ="40%center"|Tasks!bgcolor = "#00CCFF" width="15%dce6f1"|Expertise[[Image:bioteque.png|thumb|center|100px|<center>Bioteque</center>]]
|-
|-
| Design input documents linked to the product performance specificationsalign = "center"|<font color="#0000FF"><u>[http://www.appliedmed.com/products/product_card.aspx?section=professionals&proceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents Silhouette ]</u></font>|align = "center"|# Compare product specifications to design inputs|align = "center"| # Check whether appropriate verifications and validations are performed|Coil-reinforced; SL-6® hydrophilic coating# Establish if all specifications are linked to design inputs|Patency Device|align = "center"| |align = "center" |[[Image:silhouette.png|thumb|center|100px|<center>Silhouette</center>]]
|-
|-
| Appropriate design verification and validations (DValign = "center"|<font color="#0000FF"><u>[http://www.appliedmed.com/products/product_card.aspx?section=professionals&V) are performedproceGroupID=4&groupName=Urology&catID=37&Name=Ureteral+stents 7-10 endopyelotomy]</u></font>|align = "center"| # Show DV&V criteria are based on risk management requirements|align = "center"| |Proprietary thermoplastic elastomer material; SL-6® hydrophilic coating|Dual Diameter stent|align = "center"| |align = "center" |[[Image:Applied_7_10.png|thumb|center|100px|<center>Endopyelotomy Stent</center>]]
|-
| Product performance specifications correspond to appropriate design output documentsalign = "center" bgcolor = "#dce6f1" rowspan = "6"|'''9'''| align = "center" bgcolor = "#dce6f1" rowspan = "6"|<font color="#0000FF"><u>[http://www.bardurological.com/products/categoryTwo.aspx?bUnitID=3&catOneID=71 Bard Urological]</u></font>|align = "center" bgcolor = "# Correlate design drawings with the specificationsdce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=225 InLay Optima]</u></font>|align = "center" bgcolor = "# Check whether maximum dimensions, sizes etcdce6f1"|<font color="#0000FF"><u>[http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=16869 FDA 510(with tolerancesk) are within the specified range]</u></font>|align = "center" bgcolor = "#dce6f1"|Dec, 2004|bgcolor = "#dce6f1"|Silicone|bgcolor = "#dce6f1"|Double pigtail with monofilament suture loop|align = "center" bgcolor = "#dce6f1"|365|align = "center" bgcolor = "#dce6f1"|[[Image:InLay_Optima.png|thumb|center|100px|<center>InLay Optima</center>]]
|-
|-
| DFMEA links appropriately to the PPSalign = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=228 Fluoro-4 Silicone Ureteral Stent]</u></font>|align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "# Verify whether DFMEA and product specifications are correlateddce6f1"| |bgcolor = "#dce6f1"|Silicone/tantalum|bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"|[[Image:Fluoro_4.png|thumb|center|100px|<center>Fluoro 4</center>]]
|-
| Appropriate DValign = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.bardurological.com/products/loadProduct.aspx?bUnitID=3&V reports and design output documents are referenced correctly as risk mitigation activities in the DFMEAprodID=230 Figure-4 Silicone Ureteral Stent]</u></font>|align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "# Validate the process and correlate with dce6f1"| |bgcolor = "#dce6f1"|Silicone|bgcolor = "#dce6f1"|Three dimensional design inputs|align = "center" bgcolor = "# Validate that sizes used are within range of risk mitigation criteriadce6f1"| |align = "center" bgcolor = "#dce6f1"|[[Image:Figure_4.png|thumb|center|100px|<center>Figure 4</center>]]
|-
| PFMEA links appropriately to the process validation protocol acceptance criteria; In-process inspection procedures andalign = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http:/or manufacturing procedures are recorded as appropriate risk mitigation activities in the PFMEA/www.bardurological.com/products/loadProduct.aspx?bUnitID=3&prodID=226 InLay Ureteral Stent]</u></font>| align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=122796 FDA 510(k)]</u></font>|align = "center" bgcolor = "# Validate the process protocoldce6f1"|Dec, 1998|bgcolor = "# Validate the inspection procedures used dce6f1"|Silicone|bgcolor = "#dce6f1"|Tapered tip and lubricious hydrophilic coating |align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "#dce6f1"|[[Image:InLay.png|thumb|center|100px|<center>InLay</center>]]
|-
|-
| Correlate First Article Inspection data to the dimensions on the drawingsalign = "center" rowspan = "4"|'''10'''| align = "center" rowspan = "4"|<font color="#0000FF">[http://www.coloplast.com/Pages/home.aspx Coloplast-Porges]</font>|align = "center"|<font color="# Obtain First Article Inspection data0000FF"><u>[http://www.porges.ru/catalog.html?cid=251 Vortek]</u></font>|align = "center"|<font color="# Check if this data correlates with the completeness of drawings0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=121312 FDA 510(k)]</u></font>|align = "center"|Oct, 1998|Silicone|Double coating for easy maneuverability as well as flexibility|align = "center"| |align = "center"|[[Image:Vortek.png|thumb|center|100px|<center>Vortek</center>]]
|-
|-
| Linkage between component and raw material specifications and appropriate incoming inspection proceduresalign = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=249 Polyurethane]</u></font>|align = "center"| # Identify any missing documentation |align = "center"| |Hard or soft Polyurethane|Designed for inspection proceduresshort-term use|align = "center"| 90|align = "center"|[[Image:Polyurethane1.png|thumb|center|100px|<center>Polyurethane</center>]]
|-
|align = "center"|<font color="#0000FF"><u>[http://www.porges.ru/catalog.html?cid=250 Silicone]</u></font>
|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=6586 FDA 510k)]</u></font>
|align = "center"|Oct, 2002
|Silicone
|''Pyatiprofilnaya'' technology
|align = "center"|
|align = "center"|[[Image:Silicone1.png|thumb|center|100px|<center>Silicone</center>]]
|-
| Inspection procedures have adequate sampling plans based on PFMEA risk mitigation levels – this includes packaging align = "center" bgcolor = "#dce6f1"|'''11'''|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF">[http://www.teleflex.com/en/emea/productAreas/urology/index.html Teleflex Medical]</font>|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.google.com/url?sa=t&source=web&cd=3&ved=0CCQQFjAC&url=http%3A%2F%2Fwww.myrusch.com%2Fimages%2Frusch%2Fdocs%2FU62C.pdf&rct=j&q=DD%2Bureteral%2Bstent&ei=CcY-TeDWHcrirAfyr4naCA&usg=AFQjCNHSSc9r_DBwotSa_oszWLYMPRuoYg&cad=rja Rüsch Superglide DD]</u></font>|align = "center" bgcolor = "#dce6f1"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=122381 FDA 510(k)]</u></font>|align = "center" bgcolor = "#dce6f1"|Jul, 1999|bgcolor = "#dce6f1"| WIRUTHAN® (polyurethane) with hydrogel coating|bgcolor = "#dce6f1"| Directable and labeling materialsdetachable|align = "center" bgcolor = "#dce6f1"| |align = "center" bgcolor = "# Review supplier audit reports for compliancedce6f1"|[[Image:Superglide_DD.png|thumb|center|100px|<center>Superglide DD</center>]]
|-
| Calibration records and preventive maintenance records; inalign = "center" rowspan = "9"|'''12'''|align = "center" rowspan = "9"|<font color="#0000FF">[http://www.gyrusacmi.com/user/display.cfm?display=cat_menu&maincat=Stone%20Management&catid=122 Gyrus ACMI/Cabot/Acromed/Circon/Surgitek]</font>|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9257&catid=122&maincat=Stone%20Management&catname=Stents Classic closed-process tip]</u></font>|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=68160 FDA 510(k)]</u></ incoming inspection test methods and related test method validationsfont>|align = "center"|Dec, 1986
|
|-
|-
| Design test methods align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9256&catid=122&maincat=Stone%20Management&catname=Stents Double-J]</u></font>|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=74392 FDA 510(k)]</u></font>|align = "center"|Apr, 1988|Silicone|Double-J closed-tip |align = "center"| |align = "center"|[[Image:Gyrus_Double_J.png|thumb|center|100px|<center>Double_J</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9254&catid=122&maincat=Stone%20Management&catname=Stents Lithostent]</u></font>|align = "center"| |align = "center"| |Tecoflex® |Grooved design|align = "center"| |align = "center"|[[Image:Lithostent.png|thumb|center|100px|<center>Lithostent</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9253&catid=122&maincat=Stone%20Management&catname=Stents Lubri-flex]</u></font>|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=91169 FDA 510(k)]</u></font>|align = "center"|Nov, 1991|Tecoflex®|“Rememberance” of shape with a chemically bonded wettable solution |align = "center"| |align = "center"|[[Image:Lubri_Flex.png|thumb|center|100px|<center>Lubri-flex</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9250&catid=122&maincat=Stone%20Management&catname=Stents Multi-flex]</u></font>|align = "center"| |align = "center"| |Tecoflex®|Two durometers with helical kidney curls|align = "center"| |align = "center"|[[Image:Multi_Flex.png|thumb|center|100px|<center>Multi-flex</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9255&catid=122&maincat=Stone%20Management&catname=Stents Quadra-Coil multi-length]</u></font>|align = "center"|<font color="#0000FF"><u>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=107077 FDA 510(k)]</u></font>|align = "center"|Mar, 1996|Tecoflex®|Accomodate ureteral lengths from 22cm to 28cm|align = "center"| |align = "center"|[[Image:Quadra_Coil.png|thumb|center|100px|<center>Quadra-Coil</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9249&catid=122&maincat=Stone%20Management&catname=Stents Sof-curl]</u></font>|align = "center"| |align = "center"| |Tecoflex®|Dual-durometer design and related test method validationsexclusive soft bladder helix |align = "center"| |align = "center"|[[Image:Sof_curl.png|thumb|center|100px|<center>Sof-curl</center>]]|-|align = "center"|<font color="#0000FF"><u>[http://www.gyrusacmi.com/user/display.cfm?display=product&pid=9258&catid=122&maincat=Stone%20Management&catname=Stents Uroguide]</u></font>|align = "center"| |align = "center"| |Silicone|Classic Double J with open tip|align = "center"| |align = "center"|[[Image:Uroguide.png|thumb|center|100px|<center>Uroguide</center>]]|-|align = "center" bgcolor = "#dce6f1"|'''13'''|align = "center" bgcolor = "#dce6f1"|[http://www.amecath.com/ Ameco Medical Industries]|align = "center" bgcolor = "#dce6f1"|[http://www.amecath.com/ Amecath]|bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"| |bgcolor = "#dce6f1"|Nitinol; Available with hydrophilic coating|bgcolor = "#dce6f1"|Double loop stent|align = "center" bgcolor = "#dce6f1"|Short-term and long-term|align = "center" bgcolor = "#dce6f1"|[[Image:Amecath.png|thumb|center|100px|<center>Amecath</center>]]|-|align = "center"|'''14'''|align = "center"|[http://www.zapconnect.com/companies/index.cfm/fuseaction/companies_detail/eregnum/9681442.html Angiomed-Movaco (C.R. Bard subsidiary)]|align = "center"|[http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K864225 Ureteral Stent Set]|align = "center"|[http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pmn&id=K864225 FDA 510(k)]|align = "center"|Jan, 1987|Nitinol|Self-expanding stent
|
|-
|}
=Product to Clinical Trial Mapping= = Sample report =Clinical Timeline Visualization ==[[Image:Timeline.jpg]] [[Media:Ureteral_Stents_Timeline dw.xls|Ureteral Stent Timeline]] =Product to Patent Mapping = [[Image:Product_Patent_Mapping_Screen_Shot.png|1000px|centre|thumb|'''Screenshot for the product to patent mapping(Bard and Boston)''']]* Click [[Media:Product_Patent_Mapping_Bard_Boston.xls|'''Products from Boston Scientific and C R Bard ''']]to download the excel file.== Performance/Functional Characteristics ==Mapped Patent vs Not Mapped Patents =={| classborder="wikitable0" stylecellspacing="font-size:90%" border="10" cellpadding="54" cellspacingwidth="0100%" |[[Image:CRB_Pat.png|center|500px|thumb|'''C R Bard''']]|[[Image:BS_pat.png.png|center|500px|thumb|'''Boston Scientific''']]|- style|} ="backgroundPatent-Product-Clinical Trial Mapping= * To access the Dashboard you have to signup. You can do so by clicking [https:lightgrey//www.dolcera.com/auth/index.php/login '''here''']*''Use the mouse(click and drag/scroll up or down/click on nodes) to explore nodes in the detailed taxonomy''*''Click on the red arrow adjacent to the node name to view the content for that particular node in the dashboard'' *''Click on the "+" sign to zoom the mindmap and "-" sign to shrink the mindmap''!align {|border= "center2" bgcolor cellspacing= "#00CCFF0" colspan cellpadding= "4" width="100%" |Design Input<mm>[[ureteral_stent_mapping1.mm|flash|Ureteral Stent mindmap|600pt]]</mm> |} !align =Insights= {|border= "center2" bgcolor cellspacing= "#00CCFF0" cellpadding="4" width="5100%" rowspan|bgcolor ="2#538ED5"|Design Output!align <font size = "center4" >''' '''</font>|bgcolor = "#00CCFF538ED5" width|<font size ="5%4" rowspan>''' '''</font>|bgcolor ="2#538ED5"|Design Verification Report #!align <font size = "center4" >'''Boston Scientific'''</font>|bgcolor = "#00CCFF538ED5" width|<font size ="5%4" rowspan="2"|Status (P>'''C R BARD'''</F/R)font>!|-|align = "center" bgcolor = "#00CCFF" width="5%538ED5" rowspan="24"|Design Validation Report #'''Products'''!|'''Portfolio'''|8 Products|6 Products|-|'''Material'''|Percuflex - Biocompatible Polymer|Silicone|-|'''Coating'''|Hydroplus|Licensed from pHreecoat|-|'''Shape'''|Pigtailed and More|Figure 4 and more|-|align = "center" bgcolor = "#00CCFF538ED5" width|'''Clinical <br>Trials'''|'''Current Trials'''|Truimph Ureteral stent - Loaded with Triclosan <br>Currently in Phase II (Canada)|None|-|align ="5%center" bgcolor = "#538ED5" rowspan="23"|Status (P/F'''Patents'''|'''Coating'''|Therapeutic /R)Medicinal coatings <br>Magnetic nano particles for MRI Imaging <br>Lubricious coatings helping easy insertion|Therapeutic coatings
|-
|-
|Provide antimicrobial resistance for up to 2 weeks'''Material'''|Ureteral Elastically deformable stents<br>Biodegradable polymer based stents<br>Porous polymer for long term implantation<br>Stent User Survey (Document #XXXXX)|Stent must have chlorohexadine surface concentration of 10-20 mg/cm2 for 3 weeks|Document #XXXXX|Test Document #XXXXX|Report 01-005-06-007|P|Report 01-005-06-007with variable hardness|PBiodegradable polymers<br>Shape memory alloys<br>General polymer based
|-
|}
== Phase 3: Post-acquisition integration Inference ===== Deadlines ==='''Goal''': Switch production transparently to new facilities transparently to the distribution system
{| classborder="wikitable2" stylecellspacing="font-size:90%" border="10" cellpadding="54" cellspacingwidth="082%" |- style="background:lightgrey"!align = "center" bgcolor = "#00CCFF538ED5" |Stage!align <font size = "center" bgcolor = "#00CCFF4" >'''Boston Scientific'''</font>|Tasks!align = "center" bgcolor = "#00CCFF538ED5" |Milestone payment!align <font size = "center4" bgcolor = "#00CCFF" |Date>'''C R BARD'''</font>
|-
|Design center integration planRelatively late entrant with patents filed post mid 90s|* Gap analysis completion (acquiree)* Gap analysis completion (acquirer)||September 15, 2008Early mover with patents filed in mid 80s
|-
|Design to manufacturing transferIncreased patent activity since 2000|||December 15, 2008Patent activity never gained traction
|-
|Equipment transferLarge number of patents yet to be "productized"||Milestone I payment|Jan 7, 2009Few patents yet to be "productized"
|-
|Shut production at acquiree facilitySome products undergoing clinical trails|Negotiation for contract extension|Milestone II payment|Feb 15, 2009No products undergoing clinical trails
|-
|Start production Diverse range of products with variation in acquirer facilitymaterial <br>and structure|||Feb 7, 2009Small product portfolio
|-
|Switch Seem to new SKUbe strengthening they market position|||Feb 15, 2009Seem to be moving focus away from Ureteral stents market
|-
|End development } = Competitive Landscape ===Major Players==*Boston Scientific Limited, Abbott, Medtronic and Cook Inc. are the major players in ureteral stent research field. [[Image:Major playersnew.jpg|thumb|center|1000px|Major Players]] ==IP Activity==*Patenting activity has been high growth rate during the period 2001 to 2005 with a peak no. of new generation product/s patents in old facilityyear 2005, followed by saturation during the period 2006 to 2008 and after that a gradual declination upto year 2010 in the ureteral stent research area.[[Image:IPactivity3.png|thumb|center|1000px| IP activity over the years]] ==Sales == Total Sales in 2010 - 4.04 Billion USD {|border="2" cellspacing="0" cellpadding="4" width="100%"|Feb 7, 2009bgcolor = "#4f81bd"|'''Company'''|bgcolor = "#4f81bd"|'''Total Sales in 2010'''|bgcolor = "#4f81bd"|'''Urological sales'''|bgcolor = "#4f81bd"|'''Percentage share'''|bgcolor = "#4f81bd"|'''Product portfolio'''
|-
|Restart development of new generation productbgcolor = "#4f81bd"|'''Boston Scientific'''|7800|661|8.48|<font color="#0000FF"><u>[http:/s post/www.bostonscientific.com/templatedata/imports/Microsite/Stone/collateral/Percuflex-acquisitionBrochure.pdf Boston_portfolio]</u></font>|-|Final milestone paymentbgcolor = "#4f81bd"|'''CR BARD'''|Mar 1, 20092700|702|26.00|<font color="#0000FF"><u>[https://dolcera.net/teamwiki_prod/index.php/BARD_portfolio BARD_portfolio]</u></font>|-|bgcolor = "#4f81bd"|'''Cook Medical'''|1700|<nowiki>-</nowiki>|<nowiki>-</nowiki>|<font color="#0000FF"><u>[http://www.cookmedical.com/uro/familyListingAction.do?family=Ureteral+Stents Cook_portfolio]</u></font>|-|bgcolor = "#4f81bd"|'''Medline'''|4040|<nowiki>-</nowiki>|<nowiki>-</nowiki>|<font color="#0000FF"><u>[http://www.medline.com/irj/catalog/search?initialSearchTerms=ureteral%20stent Medline_portfolio]</u></font>
|-
|}
|-
|Product performance specificationsalign = "center"|Paul Swain[http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]|07align = "center"| [http:/27/2008 08www.dolcera.com/website_prod/services/business-research-services Market Research Services]|align = "center"| [http:15:35 PST//www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|Component specificationsalign = "center"|Kevin Teller[http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]|06align = "center"| [http:/12/2008 12www.dolcera.com/website_prod/research-processes Dolcera Processes]|align = "center"| [http:22:07 PST//www.dolcera.com/website_prod/industries Industry Focus]
|-
|Preclinical test resultsalign = "center"|Joanne Krannert|07[http:/03/2008 14:17:00 PST|www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]|Clinical testsalign = "center"|Joanne Krannert[http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]|08align = "center"| [http:/01/2008 08:00:55 PSTwww.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
<br>
=[[Backup]]=